BioSpace News Archive

Enzolytics, Inc. announced it has engaged TEN Associates LLC to assist the Company in disseminating and updating meaningful, relevant and factual information about Enzolytics, and its progress in fulfilling its business strategy, to market makers, the brokerage community, individual investors, the media and the public.

Nextech Systems, a leading provider of healthcare technology solutions for specialty providers, today announced its new partnership with PRISM Vision Group, the largest vertically-integrated eye care services organization in the Mid-Atlantic region.

Nanowear www.nanowearinc.com, the leading nanotechnology and A.I.-based remote diagnostic company, today announced a commercial distribution partnership with a world leading aesthetic and reconstructive surgical device-manufacturer, to enhance and optimize post-surgical recovery for both patients and surgeons.

CAGE Bio Inc., a biotechnology company focused on developing innovative therapies for infection, inflammation and immunology, announced dosing of the first patient in its Phase 2 clinical trial for the treatment of inflammatory lesions of rosacea.

Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, announced today progress in its MYC-synthetic lethal (MYC-SL) programme.

RNA Disease Diagnostics, Inc. (RNADD), a company developing a best-in-class molecular diagnostics platform for infectious disease detection, announced today that it held an inaugural joint meeting of its Board of Directors and Advisory Board on May 10, 2021. The newly expanded Board of Directors and Advisory Board will work alongside the leadership team to advance RNADD’s proprietary Antisense

Study shows automated pupillometry provides reliable and objective pupil reactivity measurements that may impact treatment decisions for stroke patients

SOTIO , a clinical stage immune-oncology company owned by PPF Group, today announced the presentation of a virtual poster at the 2021 ASCO Annual Meeting.

CytoSorbents Corporation (NASDAQ: CTSO), a critical care leader commercializing its CytoSorb ® and other blood purification technologies to treat deadly conditions in critically-ill and cardiac surgery patients around the world, announced the U.S Army Medical Research and Development Command has awarded CytoSorbents a contract

Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, and Numinus Wellness Inc. (“Numinus”) (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, have met another early milestone in the development of an initial all natural psilocybin extract.